Replies to post #154074 on Biotech Values

[jq1234]

RIGL: Humira 39% was ACR20 at 3-month in one toficitinib trial, 47% was ACR20 at 6 month in another toficitinib trial. Most importantly both 39% and 47% ACR20 you cited and by previous poster are not apple to apple comparison with fostamatinib ph2b trial population. PFE trials were for patients who had inadequate response to DMARD (excluding Humira) in one or inadequate response to MTX in the other while this fostamatinib trial included patients who are DMARD naive or intolerant or inadequate response to DMARD (nonbiologic) - don't know proportion of patients in the first two groups. Theoretically, Humira in this setting should have higher ACR20 at 6-month than in two toficitinib trials.